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ABSTRACT   
Context. Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and 
better survival in patients with advanced adrenocortical cancer (ACC). A correlation between 
mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting.                                      
Objective. To compare recurrence-free survival (RFS) in patients who reached and maintained  
mitotane concentrations ≥ 14 mg/l versus patients who did not.                                                                                                                                                                       
Design and setting. Retrospective analysis at 6 referral European centers.                                                              
Patients. Patients with ACC who were radically resected between 1995 and 2009 and were treated 
adjuvantly with mitotane targeting concentrations of 14–20 mg/l.                                                   
Main outcome measures. RFS (primary) and overall survival (secondary).                            
Results. Of  the 122 patients included, 63 patients (52%) reached and maintained during a median 
follow-up of 36 months the target mitotane concentrations [group 1] and 59 patients (48%) did not 
[group 2]. ACC recurrence was observed in 22 patients of group 1 (35%) and 36 patients in group 2 
(61%). In multivariable analysis, the maintenance of target mitotane concentrations was associated 
with a significantly prolonged RFS (HR of recurrence, 0.418, 0.22-0.79; P=0.007) while the risk of 
death was not significantly altered (HR, 0.59, 0.26-1.34; P=0.20). Grade 3-4 toxicity was observed 
in 11 patients (9%) and was managed with temporary mitotane discontinuation. None of the patients 
discontinued mitotane definitively for toxicity.                                                                  
Conclusions. Mitotane concentrations ≥14 mg/l predict response to adjuvant treatment being 
associated with a prolonged RFS. A monitored adjuvant mitotane treatment may benefit patients 
after radical removal of ACC. 
 
INTRODUCTION 
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumor showing an annual 
incidence of 0.5–2 cases per million population (1, 2). Surgery is the mainstay of therapy and 
complete surgical removal of ACC is the most important prognostic factor for long-term survival 
together with stage. Recurrence after apparently complete resection is frequent and may be found in 
up to 70–85% of patients with high proliferation index or locally advanced disease (3-7), an 
observation suggesting that adjuvant treatment concepts have a major role in ACC management.  
The adjuvant use of mitotane (o,p′-DDD), an adrenolytic drug used for treating advanced ACC 
since the 1960s (3, 4, 8), has become increasingly popular after the demonstration that post-
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operative mitotane treatment was associated with a significantly reduced risk of recurrence and 
death in a large series of patients with radically operated ACC (9, 10). Given its retrospective 
nature, however, this study could not provide a definitive demonstration of efficacy of mitotane in 
the adjuvant setting  (11, 12).  
For most experts, monitoring of plasma mitotane levels is currently part of the management of ACC 
patients treated with mitotane because the drug is known to have a narrow therapeutic window (13). 
Indeed, mitotane plasma levels have been shown to be associated with both therapeutic efficacy and 
drug-related toxicity in advanced ACC (14, 15) and a recent study has confirmed that a mitotane 
concentration above 14 mg/l is a predictor of tumor response and better survival (16). A similar 
strategy of targeting a threshold of 14 mg/l has been advocated in the adjuvant setting, despite the 
fact that it is presently unknown if the relationship between plasma concentrations of mitotane and 
its efficacy is  applicable also to patients treated adjuvantly without evidence of disease (13, 17).  
The aim of the present retrospective multicenter study was to evaluate whether mitotane plasma 
concentrations are associated with the outcome of patients receiving adjuvant mitotane treatment 
following radical resection of ACC. We assessed whether the currently used threshold of 14 mg/l 
may predict a beneficial effect of the drug  on recurrence free survival. 
 
 METHODS 
 
Patients 
We performed a retrospective analysis among patients with ACC who had undergone radical 
surgery between January 1995 and December 2009 at six tertiary referral centers in Europe (S. 
Luigi Gonzaga Hospital, Orbassano, Italy; Institute Gustave Roussy, Villejuif, France; University 
Hospital of Würzburg, Würzburg, Germany; Erasmus Medical Centre, Rotterdam, Academic 
Medical Centre, Amsterdam and Maxima Medical Center, Eindhoven, The Netherlands) 
participating in the European Network for the Study of Adrenal Tumors (ENSAT; www.ensat.org). 
All patients who had undergone radical resection and monitored adjuvant mitotane treatment were 
included in the study. Follow-up for this study was closed in December 2010. During the study 
period, adjuvant mitotane was recommended in patients at perceived high risk of recurrence 
in all centers but two. At Orbassano, the policy was to recommend adjuvant mitotane 
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treatment to all patients following resection of ACC, while at Wurzburg the policy was until 
2006 to offer mitotane only to "high risk patients", and in 2006-2009 to all patients. 
To be eligible to this study the patients had to meet the following inclusion criteria: age of 16 years 
or older, histologically confirmed diagnosis of ACC, complete tumor resection, availability of 
postoperative follow-up information including results of imaging tests (CT or MRI scans) and 
regular determinations of plasma mitotane concentration. Exclusion criteria were macroscopically 
incomplete resection, incomplete tumor staging, concomitant cancers within the previous 5 years 
except for non melanoma skin cancer radically treated, clinically significant concomitant disease, 
incomplete follow-up information or follow-up duration of less than 6 months, initiation of 
mitotane treatment longer than 6 months after surgery, and concomitant postoperative adjuvant 
therapies (chemotherapy or radiotherapy). 
All data were obtained by reviewing patient history, discharge summaries, medical records, and 
source documents. Data were retrieved by trained medical personnel using specifically tailored data 
forms. We collected data on clinical and demographical characteristics, the date of diagnosis, the 
stage at diagnosis, the hormonal workup, the date and type of surgery, the pathology report, the date 
of recurrence, and either the date and cause of death or the date of the last follow-up visit. The 
following information concerning mitotane treatment was collected: treatment dose and duration, 
adverse effects, reasons for discontinuation, and results of monitoring of plasma concentrations. 
The institutional ethics committee at each clinical center approved the study except that in The 
Netherlands where retrospective use of anonymously treated data does not need to be approved by 
ethics committees (http://www.ccmo.org). All patients provided written informed consent. 
R0 resection was defined as no evidence of macroscopic residual disease on the basis of surgical 
reports, histopathological analysis, and postoperative imaging. All diagnoses were confirmed by 
experienced pathologists according to the Weiss criteria with a score of 3, or more, identifying 
malignancy (18, 19). Staging at diagnosis was based on imaging studies and was corroborated by 
the findings at surgery. Staging was reported according to the ENS@T staging system (20). Disease 
recurrence was defined as radiologic evidence of a new tumor lesion during follow-up.  
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Study protocol 
During the study period, monitored mitotane treatment aimed at reaching and maintaining a target 
plasma concentration of 14 - 20 mg/l (13, 17) was a  standard of care following removal of ACC in 
the participating centers. In the absence of intolerability to mitotane, adjuvant treatment was 
scheduled for at least 2 years, or until ACC recurrence.  
All patients received the same mitotane formulation (Lysodren, 500 mg tablets) that was purchased 
by Bristol-Meyers Squibb, USA, until 2003 and thereafter by Laboratoire HRA Pharma, France. 
Mitotane was given orally following a schedule of progressive dose increments according to local 
protocols and patient compliance aiming to reach concentrations between 14–20 mg/l (14, 15). 
When such or even higher concentrations were attained, doses were tapered with further individual 
dose adjustments guided by the results of mitotane measurement and toxicity assessment. In the 
event of unacceptable side effects, the patients were allowed to return to a lower dose or discontinue 
mitotane temporarily restarting with a lower dose. All patients received glucocorticoid replacement 
and dosing of steroid replacement was adjusted on the basis of clinical and biochemical evaluation. 
At Orbassano, 50 - 75 mg daily of cortisone acetate was used in most patients, while at the 
other centers 30 – 50 mg daily of hydrocortisone was used. Thyroxine and  sex steroid hormone 
replacement was given if deemed appropriate (13, 17). Testosterone replacement was done using 
mainly testosterone enanthate. 
Follow-up protocols were similar in the centers including imaging of both chest and abdomen at 
baseline (before introducing mitotane) and thereafter every 3-6 months until disease progression or 
end of the study period. At each visit, the patients underwent physical examination, routine 
laboratory evaluation, monitoring of mitotane concentrations and hormonal work-up. Mitotane-
related toxicity was graded using NCI CTCAE criteria version 3.0 (21).  
 
Outcomes 
The primary aim of our study was to compare recurrence-free survival (RFS) in patients who 
received adjuvant mitotane therapy after radical resection and maintained the target plasma 
concentrations with that of patients who did not. For the purpose of this analysis, we arbitrarily 
defined two groups: (1) patients who reached a mitotane plasma concentration of 14 mg/l, or 
greater, and maintained this target level in at least 75% of all measurements thereafter; (2) patients 
who either never reached a plasma level of 14 mg/l or could not maintain this level. Secondary 
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outcome measures were overall survival (OS) and adverse events associated with target mitotane 
concentrations.  
RFS was measured from the date of surgery to the date of recurrence or death, whatever event 
occurred first; for patients who did not have a relapse or died, the data were censored at the date of 
the last follow-up visit. OS was measured from the date of surgery to the date of death, and the data 
were censored at the date of the last follow-up visit. 
Statistical analysis 
Database management and all statistical analyses were performed by using the ‘Statistica’ for 
Windows software package (Statsoft Inc., Tulsa, OK, USA). Rates and proportions were calculated 
for categorical data, and median and ranges for continuous data. Normality of data was assessed by 
the Wilk–Shapiro's test and since data were not normally distributed, the two-tailed Mann–Whitney 
U test was used to assess differences in continuous variables. Differences between categorized 
variables were analyzed by the chi-square test. Survival curves were computed according to the 
Kaplan–Meier method and were compared by means of the log-rank test. A Cox proportional-
hazards regression analysis was used to assess in univariable and multivariable analysis the 
predictive role of maintenance of plasma mitotane concentrations of 14 mg/l or higher. Independent 
variables included in the multivariable analysis were the time elapsed to achieve those 
concentrations, sex (male versus female), age at diagnosis (continuous variable), ENS@T stage (I 
versus II versus III), hormone secretion (yes versus no), Weiss score and mitotic index (mitosis 
count ≥9/50 HPF versus <9/50 HPF). The mitotic index of 9/50 HPF was previously demonstrated 
by our group to have an independent adverse prognostic effect on either RFS or OS in a cohort of 
92 patients with ACC (22).  Missing data were dealt with by excluding patients from particular 
analyses if their files did not contain data for the required variables. All reported P values are two-
sided. P values of less than 0.05 were considered to indicate statistical significance.  
RESULTS 
One hundred twenty-two patients entered the study. Their baseline characteristics are provided in 
Table 1. Mitotane was given according to a low dose start-up regimen, defined as less than 6 
grams daily at the 14th day of treatment, in 77 patients (63.1%) while a high-dose start-up 
regimen, defined as more than 6 grams daily, or more, at the 14th day of treatment, was followed 
in 45 patients (36.9%), according to local preferences. The 2 groups of patients did not differ for 
baseline characteristics and the percentage of patients attaining plasma mitotane levels of 14 
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mg/l, or higher, within 3 months (Table 2). The median interval between tumor resection and 
initiation of mitotane was 2 months (1- 4 months). The median follow-up period after surgery was 
36 months (7-169 months) and the median duration of mitotane treatment was 25 months (6-165 
months). 
Of  the 122 patients included in the study, 63 patients (52%) maintained in at least 75% of the 
available determinations during follow-up the target plasma mitotane concentrations of at least 
14 mg/l, or higher, [group 1] and 59 patients (48%) did not [group 2]. On average, mitotane 
measurements were done every 3 months in 86 patients and every 6 months in 36 patients. The 
median follow-up duration was 40 months (11-169 months) in group 1 and 34 months (7-156 
months) in group 2. A flow-chart of the patients stratified according to the plasma mitotane 
threshold of 14 mg/l and time needed to reach that concentration is provided in Figure 1.  
During follow-up, ACC recurrence was observed in 58 patients (47.5%), 22 in group 1 (35.0% of the 
group) and 36 in group 2 (61.0% of the group). Death from ACC was reported for 33 patients 
(27.0%), 13 in group 1 (20.6% of the group) and 20 in group 2 (34% of the group). At the last 
follow-up visit, 89 patients were alive and 59 were on mitotane treatment, 38 of whom were free 
of recurrence. Thirty patients had discontinued mitotane after at least 6 months of treatment for 
their willingness or following recommendation of their physicians. 
In univariable analysis, the maintenance of serum mitotane concentrations of 14 mg/l, or higher, 
was associated with longer RFS (HR of recurrence, 0.497; 95% CI, 0.292-0.844; P=0.01) and OS (HR 
of death, 0.511; 95% CI, 0.253-1.029; P=0.06) (Figure 2a and 2b). The median RFS was not attained 
in group 1, and 21 months (95% CI, 6-36 months) in group 2.  The median OS was not attained in 
group 1, and 98 months (95% CI, 50-145 months) in group 2 according to the log-rank test. A rapid 
achievement (within 3 months) of mitotane levels of 14 mg/l, or higher, did not influence either 
RFS or OS among the patients who maintained target mitotane concentrations (Supplemental 
Figure 3a and 3b). The results of the multivariable Cox proportional hazards models are shown in 
Table 3. After adjustment for sex, age at diagnosis, ENS@T stage, hormone secretion, Weiss score 
and mitotic index, the patients who maintained target mitotane concentrations showed a 
significantly reduced risk of recurrence (adjusted HR, 0.418; 95% CI, 0.22-0.79; P=0.007) while the 
risk of death was not significantly altered (adjusted HR, 0.59; 95% CI, 0.26-1.34; P=0.20). Ad hoc 
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analysis including time elapsed from surgery to adjuvant treatment and follow-up duration did not 
alter the results. 
The adverse events associated with mitotane therapy are listed in Table 4. Overall, grade 3-4 
toxicity was observed in 11 patients (9%) and was managed with temporary mitotane 
discontinuation. None of the patients discontinued mitotane definitively for toxicity. 
Gastrointestinal and liver toxicities were more severe in patients treated with the high dose start-
up regimen and in this group temporary discontinuation of mitotane was more frequent. 
 
DISCUSSION 
More than 50 years after the introduction of mitotane in clinical practice (8), its use as a 
postoperative adjunctive measure remains matter of debate (11, 12, 23).  
The present study shows for the first time that mitotane levels may influence the outcome of 
patients treated adjuvantly following radical resection of ACC and validate the concept of a 
therapeutic value for a cut-off of mitotane concentrations at 14 mg/l. Patients who were able to 
consistently maintain mitotane levels of more than 14 mg/l during follow-up had a significantly 
reduced risk of recurrence than patients who failed to do so. The apparent benefit of elevated 
mitotane concentrations was confirmed when multivariable analyses were used to adjust for the 
most important prognostic factors (13, 24, 25). OS appeared to be non-significantly prolonged in 
patients who maintained target mitotane concentrations. However, since the number of events 
(deaths) was low (27%) and the median survival was not yet reached, it is likely that the effect will 
become fully evident only after a longer duration of  follow-up. Even accepting that OS is not 
significantly extended by adjuvant mitotane, treatment may be justified because ACC events, 
such as distant and loco-regional recurrences, are clinically important for patients. Although 
mitotane may impair quality of life because of unwanted effects, treatment-related toxicity is 
sustainable; thus, extending the duration of life free of disease may benefit ACC patients since 
tumor recurrence has a great negative impact on quality of life, and either psychological or 
physical health of affected patients, and triggers even more toxic treatments. 
RFS is increasingly considered as a valid surrogate endpoint for OS in adjuvant trials being closely 
related to the efficacy of adjuvant treatment, whereas OS is usually also affected by the treatment 
adopted upon  progression (26, 27). However, RFS strongly depends on the frequency and quality 
of follow-up procedures that were comparable among the different centers.  
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The independent relationship of mitotane concentration with RFS observed in this study is a further 
step toward demonstration of efficacy of mitotane in an adjuvant setting, although we cannot 
exclude that reaching target plasma concentrations is associated with unexplored patient or tumor 
features that per se could be predictive of a better prognosis.  
The available evidence on target mitotane concentrations has been obtained only in the clinical 
scenario of advanced ACC; however, most experts recommend targeting the cutoff level of 14 mg/l 
also in the adjuvant setting (13, 17). The present results validate this treatment strategy, since a 
consistent maintenance of mitotane target concentrations during treatment was an independent 
factor associated with a lower risk of recurrence. This finding is likely to have a major influence on 
clinical practice prompting a more stringent approach at maintaining target mitotane concentrations. 
The present evidence should strengthen the commitment of both patients and physicians to this task, 
that is difficult to fulfill, as shown in this study. Since levels of 14 mg/l have been targeted in our 
patients to guide mitotane dosing, we did not analyze other cut-off values that were not used 
in the clinical decision process. 
There is currently controversy on the best dosing regimen to initiate mitotane therapy. In our study, 
either high-dose or low-dose regimens were employed reflecting this controversy. A high dose 
regimen has been advocated to allow a rapid rise of plasma mitotane concentrations in order to 
avoid any delay in drug activity (28, 29); however, toxicity associated with such regimen is of 
concern. On the other hand, also a low dose regimen, potentially better tolerated, is able to provide 
target mitotane concentrations, but with a time lag of several months from treatment start (30). It is 
noteworthy that in the present series the percentage of patients attaining target mitotane 
concentrations at the landmark of 3 months did not  differ in the high-dose versus low-dose group. 
Furthermore, the time elapsed to attain target mitotane concentrations did not seem to add 
prognostic information, suggesting that shortening of this period, although plausible, is not of 
paramount importance. However, as this was not a pharmacokinetic study we cannot finally answer 
the question about the best treatment regimen.  
Toxicity was overall acceptable and it was possible to manage unwanted effects with temporary 
treatment discontinuation, or dose reduction, without losing any patient for compliance-related 
issues. Despite a possible underreporting of some adverse effects due to the retrospective nature of 
the study, we confirm that adjuvant mitotane treatment is feasible proven that a careful follow-up 
and counseling is offered to the patients. The monitoring of mitotane concentrations is of pivotal 
importance in this context to guide dose adjustments and limit unwanted effects, as it was 
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previously observed (30). Conversely, studies published before the availability of mitotane 
monitoring reported that a severe and disabling toxicity was associated with mitotane use, that may 
lead many patients to be unable to perform the usual activities of ordinary life (7).  
Our study had certain limitations, the retrospective nature and absence of randomization are the 
most important ones. To reduce selection bias that was mainly towards patients at perceived 
high risk of recurrence, we included all consecutive patients who were given adjuvant mitotane at 
the participating centers. Differences in histologic classification among the centers are unlikely, 
since all tumor specimens were reviewed by expert pathologists who used the same classification 
criteria (18, 19). Diagnostic and staging protocols were similar in all centers, and patients 
underwent surgery during the same period. Finally, follow-up procedures were largely similar 
among the centers and complete follow-up data were available for all patients. Thus, as far as can 
be stated in a retrospective study, biases appear to have been minimal.  
In conclusion, this is the first demonstration that plasma mitotane concentrations may have a 
therapeutic impact in an adjuvant setting, since mitotane levels of 14 mg/l, or higher, may prolong 
RFS in patients with radically resected ACC. This finding supports indirectly the efficacy of 
adjuvant mitotane treatment and adds to recent evidence of a beneficial effect of mitotane in an 
adjuvant setting (31, 32). Additional findings of our study that may have an impact on practice are 
that mitotane concentrations can be used as a factor predicting response to treatment, and that the 
dosing schedule used at the initiation of mitotane treatment is less important than striving for 
reaching and maintaining target mitotane levels during adjuvant therapy. This piece of evidence 
may help in structuring an articulated systemic treatment of ACC that remains challenging since the 
rarity of the disease hampered development of effective therapeutic options beyond surgery (33).  
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Table I. Baseline characteristics of the patients. 
Age, yrs  
  Median (range)  
 
45 (16-76) 
Sex,  n. (%) 
  Male 
  Female 
 
53 (43.4) 
69 (56.6) 
Tumor stage,  n. (%) 
  I 
  II 
  III 
 
10 (8.2) 
79 (64.8) 
33 (27.0) 
16 
Tumor size, cm  
 Median (Range) 
 
10.7 (3.0-25.0)  
Functional status, n. (%) 
 Secreting tumor 
 Non-secreting tumor 
 Missing 
 
65 (53.3) 
51 (41.8) 
6 (4.9) 
Weiss score  
 Median (Range) 
 
6 (2-9*) 
Mitotic index**, n. (%) 
 High 
 Low 
 Missing 
 
 
71 (58.2) 
42 (34.4) 
9 (7.4) 
*A single patient with Weiss 2 ACC recurred after 6 months.**High mitotic index is a 
mitotic count ≥9/50 HPF; low mitotic index is a mitotic count <9/50 HPF. 
 
Table II. Baseline characteristics of the patients treated according to two different 
mitotane schedules. 
 
 
Low-dose start-up regimen 
(n=77 ) 
High-dose start-up regimen 
(n=45) 
Age, yrs 
   Median (Range) 
 
44 (16-71) 
 
46 (22-76) 
Sex, n. (%) 
   Male 
   Female 
 
35 (45.5) 
42 (54.5) 
 
18 (40.0) 
27 (60.0) 
17 
Tumor stage  
   I  
   II  
   III  
 
6 (7.8) 
53 (68.8) 
18 (23.4) 
 
4 (9.0) 
26 (58.0) 
15 (33.0) 
Tumor size, cm 
   Median (Range)  
 
11  (3.0-25.0) 
 
9.7 (3.0-21.0) 
Mitotic index, n. (%)  
   High 
   Low  
   Missing 
 
48 (62.3) 
28 (36.4) 
1 (1.3) 
 
23 (51.1) 
14 (31.1) 
8 (17.8) 
Weiss score 
    Median (Range) 
 
6 (2-9) 
 
6 (3-9) 
Functional status, n. (%) 
    Secreting tumor 
    Nonsecreting tumor 
    Missing 
 
43 (55.8) 
33 (36.8) 
1 (1.3) 
 
22 (48.9) 
18 (40.0) 
5 (1.1) 
Mitotane target levels 
reached within 3 months, 
n. (%) 
   yes  
   no  
 
 
 
36 (46.8) 
41 (53.2) 
 
 
 
19 (42.2) 
26 (57.8) 
*High mitotic index is a mitotic count ≥9/50 HPF; low mitotic index is a mitotic count 
<9/50 HPF. 
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Table III – Predictive factors at multivariable analysis. 
Recurrence-free survival. 
 Hazard Ratio 95% CI p 
Sex 0.774 0.387 – 1.547 0.468 
Age at diagnosis 1.001 0.977 – 1.027 0.909 
Secreting tumor 1.864 0.93 – 3.75 0.081 
Tumor stage 1.728 0.862 – 3.464 0.123 
Weiss score 1.145 0.909 – 1.443 0.250 
High mitotic index  2.112 0.97 – 4.47 0.051 
Maintenance of mitotane 
levels ≥ 14  mg/l  
0.418 0.220 – 0.791 0.007 
 
Overall survival. 
 Hazard Ratio  95% CI p 
Sex 1.418 0.553 – 3.636 0.468 
Age at diagnosis 1.029 0.995 – 1.065 0.097 
Secreting tumor 2.31 0.80 – 6.70 0.122 
Tumor stage 1.725 0.732 – 4.064 0.212 
Weiss score 1.088 0.823 – 1.438 0.552 
High mitotic index 2.99 1.06 – 8.50 0.039 
19 
Maintenance of mitotane 
levels ≥ 14  mg/l 
0.588 0.257 – 1.344 0.208 
 
 
Table IV.  Adverse events*. 
Toxicity Grade  
 1 2 3 4 missing 
n. of patients (%) 
Neurologic 
 
19 (15.6) 7 (5.7) 7 (5.7) 0 8 (6.5) 
Hepatic 23 (18.8) 8 (6.5) 0 0 6 (4.9) 
Gastro-
intestinal 
22 (18.0) 22 (18.0) 3 (2.4) 1 (0.8) 5 (3.3) 
 
*Adverse events were graded according to the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events. Owing to the adrenolytic action of  
mitotane, all patients received prophylactic glucocorticoid replacement therapy. 
Therefore, detailed monitoring of mitotane-induced adrenal insufficiency was not 
performed. 
Because of the retrospective nature of the study, underreporting of low-grade side 
effects must be considered a possibility. 
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Figure 1.    Study population. 
Figure 2a.  Kaplan–Meier estimates for recurrence-free survival during adjuvant mitotane therapy. 
Solid line, patients with mitotane levels ≥14 mg/l during follow-up (n=63). 
Dashed line, patients with mitotane levels <14 mg/l during follow-up (n=49). 
Figure 2b.  Kaplan–Meier estimates for overall survival during adjuvant mitotane therapy. 
Solid line, patients with mitotane levels ≥14 mg/l during follow-up (n=63). 
Dashed line, patients with mitotane levels <14 mg/l during follow-up (n=49). 
Figure 3a.  Kaplan–Meier estimates for recurrence-free survival during adjuvant mitotane therapy. 
Dashed line, patients attaining mitotane levels ≥14 mg/l in ≤3 months (n=40). 
Solid line, patients attaining mitotane levels <14 mg/l in >3 months (n=23). 
Figure 3b.  Kaplan–Meier estimates for overall survival during adjuvant mitotane therapy. 
Dashed line, patients attaining mitotane levels ≥14 mg/l in ≤3 months (n=40). 
Solid line, patients attaining mitotane levels <14 mg/l in >3 months (n=23). 
